EMPOWER-Lung3 Analysis Reveals Differential Outcomes With Cemiplimab/Chemo in Genomic Subsets of NSCLC | OncLive Cemiplimab plus chemotherapy produced variable outcomes by genomic profile in patients with nonsquamous NSCLC.

🫁Varying outcomes were observed following treatment with cemiplimab-rwlc plus chemotherapy in molecularly defined subsets of patients with nonsquamous NSCLC @myesmo.bsky.social #lscm #NSCLC #oncology #ELCC26
www.onclive.com/view/empower...

📢 THIS WEEK 📢 Join us on Thursday as Dr Witold Bahr reviews mixed methods research in #SupplyChainManagement
#Methodology #Methods #ResearchMethods #LSCM

(2/2) Witold will present a review of mixed methods research across ten years in LSCM to determine their usage, identify benefits and inhibitors, and provide suggestions for LSCM researchers to realise the benefits from using mixed methods
#ResearchMethods #MixedMethods #SupplyChainManagement #LSCM

26 Real-life lung cancer stories from our community — ALL YOU NEED IS LUNGS Discover 26 powerful stories of individuals living with lung cancer. From the first symptoms and challenging diagnoses to finding strength and hope, these real-life experiences shine a light on the re...

Discover 26 powerful real-life stories from people living with #LungCancer - from first symptoms to challenging diagnoses to finding strength & hope.

Showing the realities of lung cancer & the resilience of those affected.

www.allyouneedislungs.org.uk/volunteers-v... #LSCM

Debra Montague Joins Medscape Faculty Steering Committee as Patient Representative - OncoDaily Debra Montague Joins Medscape Faculty Steering Committee as Patient Representative / ALK Positive Lung Cancer UK, Debra Montague, Lung cancer, Lung Cancer

Debra Montague, ALK+ UK Chair and Vice President of @lungcancereurope.bsky.social joins Medscape Faculty Steering Committee as Patient Representative oncodaily.com/blog/debra-m... #LSCM

I’ve got high hope for this one. Looking forward to see more data in the future #lscm #her2

Virtual Tumor Board: Stage III ALK+ NSCLC | IASLC This IASLC Virtual Tumor Board episode focuses on a patient with stage III ALK-positive NSCLC. ALK fusions are present in about 5% of NSCLC and there are now si ...

The latest @iaslc.bsky.social Lung Cancer Considered podcast with @stephenvliu.bsky.social looks at treatment for Stage 3 ALK+ #lungcancer. This episode looks at a real case & the key decisions around treatment & molecular testing.

🎧 Listen here: www.iaslc.org/iaslc-news/l...

#LSCM #ALKPositive

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer - OncoDaily Read key results of HARMONi-2 in Lancet: Ivonescimab vs. pembrolizumab in PD-L1+ NSCLC. 49% lower risk of progression

Read more about this study:
oncodaily.com/oncolibrary/...

#Cancer #CancerResearch #Medicine #Health #LungCancer #LSCM #NSCLC #Oncology #OncoDaily

Program

Research meets practice at the #LSCM conference! Looking forward to kicking off the researcher day on Feb 5 at @hankenofficial.bsky.social - and then continue with the LOGY industry conference the days after.

Programme: www.logy.fi/logistics-an...

#logistics #SCM #LOGY

Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC European approval is no longer being sought for Dato-DXd in advanced nonsquamous non–small cell lung cancer.

Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC #lscm #oncology www.onclive.com/view/daiichi...

55,400 people in the UK will be diagnosed with lung cancer this year—that’s one every 10 minutes. Early detection saves lives. Look out for signs like a persistent cough, chest pain, weight loss, or coughing up blood. Anyone can get #lungcancer. We must keep raising awareness. #LSCM

In 2021, Tina was diagnosed with Stage 4 #ALK+ #lungcancer. It was a shock—esp as a never-smoker—but she refuses to let it stop her from making plans. Her symptoms included a persistent cough & ongoing pain in her chest & upper back.

Tina’s story 👉 www.allyouneedislungs.org.uk/volunteers-v... #LSCM